MASTERCARD-INVESTOR
30.5.2024 11:36:34 CEST | Business Wire | Press release
Mastercard today announced the opening of its European Cyber Resilience Centre (ECRC) at its European Headquarters reaffirming the company’s commitment to combatting cyber threats and enhancing resilience in the region. The new state-of-the-art centre will sharpen defenses against cyber threats, speed up response times and serve as a hub for thought leadership in cybersecurity, fostering collaboration between the public and private sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530937171/en/
Mastercard European Cyber Resilience Centre Opening in Waterloo, Belgium. (From left to right) Michael Miebach, Chief Executive Officer, Mastercard, Mathieu Michel, Belgian State Secretary for Digitalisation, Mark Barnett, President, Mastercard Europe, Catherine De Bolle, Executive Director, Europol. Photo by: Nicolas Peeters. (Photo: Business Wire)
With continuous digitization and unprecedented levels of connectivity, cybercrime presents a shared challenge across all organizations. Fraudsters are using technology in more innovative and sophisticated ways to try and harm consumers and businesses. Cybercrime has turned into a global economy now estimated to be worth trillions of euros.
To address this ever-evolving threat landscape, the ECRC brings together partners from across the public and private sectors. By leveraging its facilities and diverse talent pool, it facilitates collaboration with national cyber intelligence centres, law enforcement agencies, and industry bodies across Europe.
"In today’s hyperconnected world, cybercrime is evolving and so are we. This centre will bring together the brightest minds from business, government and other sectors to stay ahead of threats and make the digital world as secure as possible. Afterall, the work to ensure people can trust that they are safe online doesn’t stop at our four walls — or our firewalls," said Michael Miebach, CEO, Mastercard.
The Centre bolsters Mastercard’s ability to combat cyber threats across the digital ecosystem and helps it protect, detect, and respond to attacks. It fosters deeper connections with customers, partners, and stakeholders and drives collaboration across the region, enhancing resilience.
The Mastercard European Cyber Resilience Centre includes a Fusion Centre, the heart of Mastercard’s organizational incident response, and a Digital Forensics Lab in addition to representatives from more than 20 teams - all crucial to running an effective Resilience Centre.
"At Europol, we are strong believers that no single actor, sector or nation, can face the threats of cybercriminals alone. Each of us has a complementary role to play. By bringing together all relevant actors, the European Cyber Resilience Centre has the potential to bring excellence into our cross-sectoral collaboration," said Catherine De Bolle, Executive Director, Europol.
"It is with great pride that I am here today for the inauguration of the Mastercard European Cyber Resilience Centre. I am delighted that Belgium has been chosen to host this first centre in Europe dedicated to cybersecurity for Mastercard, and even more so because it will be established in the heart of Walloon Brabant. We live in a world where cyber threats are omnipresent and constantly evolving. Cyberattacks know no borders and affect all sectors of our society, from the public to the private sector, from critical infrastructures to ordinary citizens. It is therefore imperative that we unite to meet these challenges with determination and efficiency. This event marks a significant milestone in our shared commitment to strengthening cybersecurity in Europe and Belgium. The European Cyber Resilience Centre represents a key initiative to promote collaboration between the public and private sector, as well as regulatory bodies. By working hand in hand, we can significantly improve our ability to prevent, detect and respond to cyber threats," said Mathieu Michel, Belgian Secretary of State for Digitalization.
The commitment to European security is reflective of Mastercard's role in powering economies and empowering people. This is underscored by its robust infrastructure, which facilitated the protection of 143 billion transactions in 2023 alone. Upholding high standards of privacy, data responsibility, and cybersecurity, Mastercard continues to deliver seamless and secure transactions while safeguarding customer information.
About Mastercard (NYSE: MA), www.mastercard.com
Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530937171/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom